Market closedNon-fractional
Lexicon Pharmaceuticals/LXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Ticker
LXRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
The Woodlands, United States
Employees
285
Website
www.lexpharma.com
LXRX Metrics
BasicAdvanced
$842M
Market cap
-
P/E ratio
-$0.82
EPS
1.38
Beta
-
Dividend rate
Price and volume
Market cap
$842M
Beta
1.38
Financial strength
Current ratio
15.584
Quick ratio
15.262
Long term debt to equity
36.333
Total debt to equity
36.78
Interest coverage (TTM)
-11.46%
Management effectiveness
Return on assets (TTM)
-40.08%
Return on equity (TTM)
-102.72%
Valuation
Price to revenue (TTM)
237.271
Price to book
1.99
Price to tangible book (TTM)
2.35
Price to free cash flow (TTM)
-2.952
Growth
Revenue change (TTM)
1,733.33%
Earnings per share change (TTM)
30.97%
3-year revenue growth (CAGR)
-47.56%
3-year earnings per share growth (CAGR)
96.14%
What the Analysts think about LXRX
Analyst Ratings
Majority rating from 5 analysts.
LXRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
57.14%
Net income
-$48M
-2.82%
Profit margin
-4,390.90%
-38.16%
LXRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.21
-$0.20
-$0.20
-
Expected
-$0.17
-$0.21
-$0.22
-$0.20
-$0.19
Surprise
25.89%
-2.21%
-7.94%
1.27%
-
LXRX News
AllArticlesVideos
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
GlobeNewsWire·2 days ago
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewsWire·3 weeks ago
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $842M as of July 27, 2024.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of July 27, 2024.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Lexicon Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.